6 research outputs found
Screening for Diabetes among Roma People Living in Serbia
Aim To investigate the prevalence of diabetes in the Roma
population in Serbia.
Methods We screened 11 urban and 8 rural Roma communities
from October 2006 to May 2008 for the presence
of diabetes. Blood glucose values, name, age, sex, presence
of diabetes, family history, and obesity were recorded.
Results We analyzed the data from 1465 Roma people,
953 women and 512 men (785 in urban and 680 in rural
communities), with mean age of 42.42 Ā± 15.69 years. Abdominal
obesity was present in 600 (41%) participants.
Eighty seven participants (5.9%) already had diabetes and
there were 76 (5.2%) newly discovered cases of diabetes
type 2. Participants with diabetes were significantly older
(F = 28.33; P < 0.01). Family history for diabetes was positive
in a third of participants. The risk for diabetes was 3.48
times higher in participants with positive family history
(odds ratio [OR], 3.47; 95% confidence interval [CI], 2.37-5.1;
P < 0.01). Abdominal obesity was less frequent in healthy
participants than in participants with diabetes (X2 = 32.55;
P < 0.01). The risk of diabetes in participants with abdominal
obesity was 2 times higher than in the non-obese (OR,
2.11; 95% CI, 1.24-3.55; P < 0.01). Diabetes was significantly
more present in urban communities (X2 = 25.20; P < 0.01).
The risk of developing diabetes was 3.65 times higher in
participants from urban settlements (OR, 3.64; 95% CI, 1.99-
6.66; P < 0.01).
Conclusion Prevalence of diabetes in the Roma people
living in Serbia may possibly be higher than in the general
population of Serbia and needs further investigation
Screening for Diabetes among Roma People Living in Serbia
Aim To investigate the prevalence of diabetes in the Roma
population in Serbia.
Methods We screened 11 urban and 8 rural Roma communities
from October 2006 to May 2008 for the presence
of diabetes. Blood glucose values, name, age, sex, presence
of diabetes, family history, and obesity were recorded.
Results We analyzed the data from 1465 Roma people,
953 women and 512 men (785 in urban and 680 in rural
communities), with mean age of 42.42 Ā± 15.69 years. Abdominal
obesity was present in 600 (41%) participants.
Eighty seven participants (5.9%) already had diabetes and
there were 76 (5.2%) newly discovered cases of diabetes
type 2. Participants with diabetes were significantly older
(F = 28.33; P < 0.01). Family history for diabetes was positive
in a third of participants. The risk for diabetes was 3.48
times higher in participants with positive family history
(odds ratio [OR], 3.47; 95% confidence interval [CI], 2.37-5.1;
P < 0.01). Abdominal obesity was less frequent in healthy
participants than in participants with diabetes (X2 = 32.55;
P < 0.01). The risk of diabetes in participants with abdominal
obesity was 2 times higher than in the non-obese (OR,
2.11; 95% CI, 1.24-3.55; P < 0.01). Diabetes was significantly
more present in urban communities (X2 = 25.20; P < 0.01).
The risk of developing diabetes was 3.65 times higher in
participants from urban settlements (OR, 3.64; 95% CI, 1.99-
6.66; P < 0.01).
Conclusion Prevalence of diabetes in the Roma people
living in Serbia may possibly be higher than in the general
population of Serbia and needs further investigation
ZnaÄaj odreÄivanja produkata uznapredovale glikacije i biomarkera lipidnog i redoks statusa kod pacijenata sa dijabetes melitusom
Non-enzymatic glycation, oxidative stress (OS) and dyslipidemia are the main
metabolic alterations behind the development of macrovascular
complications (cardiovascular diseases) of diabetes mellitus (DM).
However, clinical relevance of biomarkers of these processes in patients with microvascular
complications (nephropathy, neuropathy, retinopathy) is less understood. Therefore, the aim
of this study was to examine advanced glycation products (AGEs), biomarkers of OS, and
dyslipidemia in 100 DM patients (33 without microvascular complications and 77 with
complications) and 30 subjects without DM. AGEs levels were higher in patients with
complications than in those without complications (median: 5.72; interquartile range: 4.60-
6.54 U/mL vs. median: 4.84; interquartile range: 4.10-5.40 U/L; P<0.05). In addition to
AGEs, the group with diabetic retinopathy had higher plasma total antioxidant capacity
(P<0.05), while the group with diabetic nephropathy had smaller LDL size than the patients
without these complications (25.48Ā±1.26 nm vs. 26.21Ā±1.19 nm; P<0.05). The patients
with co-existing cardiovascular disease were further characterized by dysfunctional HDL
particles, as evidenced by increased small HDL particles (P<0.05) and reduced paraoxonase-
1 activities. Significant increase in both pro-oxidant-antioxidant balance and ischemia-
modified albumin (P<0.05), with simultaneously decreased activity of superoxide-dismutase
(P<0.05) was found in patients with progressive diabetic neuropathy, indicating the highest
degree of oxidative damage. It can be concluded that patients with microvascular
complications of DM have aggravated redox imbalance and lipid profile alterations. In
addition to metabolic control, strategies aimed at lowering OS and correcting dyslipidemia
can contribute to the prevention of microvascular complications of diabetes.Neenzimska glikacija, oksidativni stres (OS) i dislipidemija su glavni metaboliÄki
procesi koji dovode do razvoja makrovaskularnih komplikacija (kardiovaskularnih bolesti)
dijabetesa melitusa (DM). MeÄutim, kliniÄki znaÄaj odreÄivanja biomarkera ovih procesa
kod pacijenata sa mikrovaskularnim komplikacijama (retinopatija, nefropatija, neuropatija)
nije dovoljno razjaŔnjen. Cilj ovog istraživanja je bio ispitivanje produkata uznapredovale
glikacije (AGE), biomarkera OS i dislipidemije kod 100 pacijenata sa DM (33 bez
mikrovaskularnih komplikacija i 77 sa komplikacijama) i 30 ispitanika bez DM. Nivo
cirkuliÅ”uÄih AGE je bio znaÄajno viÅ”i u grupi pacijenata sa komplikacijama (medijana: 5,72;
interkvartilni raspon: 4,60-6,54 U/mL) u odnosu na pacijente bez komplikacija (medijana:
4,84; interkvartilni raspon 4,10-5,40 U/L; P<0,05). Pored poviŔenih koncentracija AGE,
pacijenti sa dijabetesnom retinopatijom su imali i poviŔene vrednosti totalnog oksidativnog
statusa (P<0,05), a pacijenti sa dijabetesnom nefropatijom manje dijametre LDL Äestica
(25,48Ā±1,26 nm) u poreÄenju sa sa pacijentima bez komplikacija (26,21Ā±1,19 nm;
P<0,05). Nadalje, kod pacijenata sa pridruženim makrovaskularnim komplikacijama
(kardiovaskularnim bolestima) utvrÄeno je prisustvo disfunkcionalnih HDL Äestica, na
osnovu poveÄanog udela malih HDL Äestica (P<0.05) i smanjene aktivnosti paroksonaze-
1. Pacijenti sa progresivnom dijabetesnom neuropatijom su imali znaÄajno poviÅ”ene
vrednosti prooksidativno-antioksidativnog balansa i ishemijom modifikovanog albumina
(P<0,05), uz istovremeno sniženje aktivnosti superoksid-dismutaze (P<0,05), Ŕto ukazuje da
je stepen oksidativnog oÅ”teÄenja u ovoj grupi bio najveÄi. Može se zakljuÄiti da, pored
adekvatne metaboliÄe kontrole, strategije usmerene ka sniženju OS i korekciji dislipidemije,
mogu doprineti prevenciji razvoja mikrovaskularnih komplikacija dijabetesa.VIII Kongres farmaceuta Srbije sa meÄunarodnim uÄeÅ”Äem, 12-15.10.2022. Beogra
Capture the fracture - use of bone turnover markers in clinical practice
Bone is a living tissue, metabolically very active, with the level of
turnover of about 10% per year. Bone remodeling is a well-balanced process of
bone resorption, induced by osteoclasts and bone formation maintained
osteoblasts. Loss of bone remodeling balance, with increased bone resorption,
leads to osteoporosis. Bone turnover markers are classified as markers of
bone formation and of bone resorption. During the growth and development of
skeleton, bone turnover markers show higher levels of activity than in the
adult period. The increase in biochemical markers peaks again in the
postmenopausal period, indicating accelerated bone remodeling. Bone mineral
density is an important predictor of an osteoporotic fracture. Timely
assessment of risk factors of osteoporosis and bone markers can detect
subjects with accelerated bone remodeling and osteoporosis. This may
introduce adequate therapy and prevent fracture
Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Non-Interventional, Multicentre Study
<p><b>Article full text</b></p><p><br></p><p>The full text of this article can
be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s13300-018-0378-4">https://link.springer.com/article/10.1007/s13300-018-0378-4</a></p><p></p><p><br></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/Ć¢ĀĀmailto:[email protected]Ć¢ĀĀ"><b>[email protected]</b></a>.</p><p> </p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as āpeer reviewedā to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>ā¢ Slide decks</p><p>ā¢ Videos and animations</p><p>ā¢ Audio abstracts</p><p>
</p><p>ā¢ Audio slides</p><ul>
</ul
The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
Introduction. A combination of drugs is required for treatment of obese
subjects with diabetes, due to multiple pathogenic mechanisms implicated in
the development of both diabetes and obesity. Objective. Assessment of the
effect of sitagliptin added to insulin glargine and metformin, in obese
subjects with type 2 diabetes. Methods. A total of 23 obese subjects on
metformin and insulin glargine participated in the study. Titration of
insulin glargine during a one-month period preceded the addition of 100 mg of
sitagliptin daily. Body mass index, waist circumference, fasting, and
prandial glucose were measured monthly, lipids and hemoglobin A1c (HbA1c)
every three months, insulin, c-peptide and glucagon at the start and after
six months of treatment. Homeostatic models for insulin secretion (HOMA B)
and insulin resistance (HOMA IR) were calculated. Results. Participants were
58.65 Š} 7.62 years of age with a body mass index of 35.06 Š} 5.15 kg/m2,
waist circumference of 115.04 Š} 15.5 cm, and the duration of diabetes of
4.11 Š} 2.57 years. With the titration of insulin glargine, target fasting
glucose levels were not achieved. Waist circumference and body mass index
decreased during three months of sitagliptin treatment, thereafter remaining
stable. HbA1c decreased significantly after three and six months of therapy.
C-peptide increased significantly, while glucagon level fell. HOMA indexes
were unchanged. Conclusion. Sitagliptin can improve diabetes control and
induce modest weight loss in obese subjects poorly controlled on insulin
glargine and metformin. Titration of insulin glargine to optimal fasting
glucose values is a prerequisite of success of this combination therapy